Pharsight

Saphris patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7741358 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(2 years from now)

US8022228 ALLERGAN Crystal form of asenapine maleate
Apr, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741358

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(3 years from now)

US8022228

(Pediatric)

ALLERGAN Crystal form of asenapine maleate
Oct, 2026

(3 years from now)

Saphris is owned by Allergan.

Saphris contains Asenapine Maleate.

Saphris has a total of 4 drug patents out of which 0 drug patents have expired.

Saphris was authorised for market use on 13 August, 2009.

Saphris is available in tablet;sublingual dosage forms.

Saphris can be used as use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; treatment of bipolar disorder and schizophrenia; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: as adjunctive treatment to lithium or valproate in adults; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes in pediatric patients age 10-17; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: acute monotherapy of manic or mixed episodes (ages 10 to adult); method of treating manic or mixed episodes associated with bipolar disorder in pediatric patients; use of the atypical antipsychotic asenapine for treatment of manic or mixed episodes of bipolar i disorder: maintenance monotherapy in adults.

The generics of Saphris are possible to be released after 06 October, 2026.

Drugs and Companies using ASENAPINE MALEATE ingredient

Market Authorisation Date: 13 August, 2009

Treatment: Use of the atypical antipsychotic asenapine for treatment of schizophrenia in adults; Treatment of bipolar disorder and schizophrenia; Use of the atypical antipsychotic asenapine for treatment of mani...

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of SAPHRIS before it's drug patent expiration?
More Information on Dosage

SAPHRIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic